Bristol-Myers Squibb

Celgene taps Bristol-Myers salesforce to bolster key blood cancer launches
Celgene taps Bristol-Myers salesforce to bolster key blood cancer launches
Fierce Pharma
Celgene
Bristol-Myers Squibb
blood cancer
Flag link:
JPM Monday roundup: No deals, but drug-pricing startup causes the biggest noise
JPM Monday roundup: No deals, but drug-pricing startup causes the biggest noise
Fierce Biotech
JPMHC 2020
M&A
Gilead Sciences
Bristol-Myers Squibb
Flag link:
JPM: Bristol chief says one-third of Celgene cost cuts will hit in 2020
JPM: Bristol chief says one-third of Celgene cost cuts will hit in 2020
Fierce Pharma
M&A
JPMHC 2020
Bristol-Myers Squibb
Celgene
Giovanni Caforio
Flag link:
A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations
A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations
Yahoo/Benzinga
JPMHC 2020
Bristol-Myers Squibb
Vertex Pharmaceuticals
Biomarin
Regeneron
Biogen
Alexion
Gilead Sciences
Amgen
Flag link:
Bristol-Myers confident of approvals linked to higher Celgene investor payout: Bristol executive
Bristol-Myers confident of approvals linked to higher Celgene investor payout: Bristol executive
Reuters
Bristol-Myers Squibb
Celgene
M&A
liso-cel
ozanimod
bb2121
FDA
Flag link:
B-MS, Sanofi Claim Hawaii is Violating Their Free Speech in Plavix Suit
B-MS, Sanofi Claim Hawaii is Violating Their Free Speech in Plavix Suit
RAPS.org
freedom of speech
Bristol-Myers Squibb
Sanofi
Hawaii
Plavix
Flag link:
A big finish confirms 2019 as a takeover year to remember
A big finish confirms 2019 as a takeover year to remember
EP Vantage
M&A
AbbVie
Allergan
Astellas
Bristol-Myers Squibb
Eli Lilly
Merck
Novartis
Pfizer
Sanofi
Flag link:
US cancer death rate drops by sharpest rate on record
US cancer death rate drops by sharpest rate on record
BioPharma Dive
cancer
Bristol-Myers Squibb
Yervoy
Merck
Keytruda
Flag link:
Bristol-Myers unloads old-school plant as it readies for CAR-T future
Bristol-Myers unloads old-school plant as it readies for CAR-T future
Fierce Pharma
Bristol-Myers Squibb
Celgene
CAR-T
M&A
Flag link:
Celgene-Seeded PharmAkea Sells Last Fibrotic Drug Candidate to Galecto
Celgene-Seeded PharmAkea Sells Last Fibrotic Drug Candidate to Galecto
Xconomy
Amira Pharmaceuticals
Bristol-Myers Squibb
Celgene
PharmAkea
Galecto Biotech
fibrotic disease
Flag link:
Top Biopharma M&As in 2019
Top Biopharma M&As in 2019
BioSpace
M&A
Bristol-Myers Squibb
Celgene
AbbVie
Allergan
Roche
Spark Therapeutics
Novartis
The Medicines Company
Alkermes
Rodin Therapeutics
Sumitomo Dainippon
Roivant
Flag link:
Pfizer, BMS, Gilead, AbbVie and others hike prices on hundreds of meds to ring in 2020
Pfizer, BMS, Gilead, AbbVie and others hike prices on hundreds of meds to ring in 2020
Fierce Pharma
drug pricing
Pfizer
Bristol-Myers Squibb
AbbVie
Flag link:
As Bristol-Myers, Pfizer battle copycat challengers in court, FDA approves generics for blockbuster Eliquis
As Bristol-Myers, Pfizer battle copycat challengers in court, FDA approves generics for blockbuster Eliquis
Endpoints
Pfizer
Bristol-Myers Squibb
FDA
generics
bloodthinners
Eliquis
Micro Labs
Mylan
Flag link:
How Gilead Sciences Is Helping Fund Bristol-Myers Squibb's Celgene Acquisition
How Gilead Sciences Is Helping Fund Bristol-Myers Squibb's Celgene Acquisition
Motley Fool
Bristol-Myers Squibb
Celgene
M&A
Flag link:
Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles
Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles
Fierce Pharma
gene therapy
reimbursement
drug manufacturing
Bristol-Myers Squibb
Pfizer
Biomarin
Sarepta Therapeutics
Gilead Sciences
CAR-T
Flag link:
After big M&A year, will pharma move away from massive deals in 2020?
After big M&A year, will pharma move away from massive deals in 2020?
Fierce Pharma
M&A
Sanofi
Merck
AbbVie
Allergan
Bristol-Myers Squibb
Celgene
FTC
Flag link:
Bristol-Myers Placed A Big Bet On Celgene’s Pipeline. Will It Pay Off For Investors?
Bristol-Myers Placed A Big Bet On Celgene’s Pipeline. Will It Pay Off For Investors?
Motley Fool
Bristol-Myers Squibb
Celgene
M&A
Revlimid
patents
Flag link:
Bristol-Myers wins $752 million in U.S. patent case against Gilead
Bristol-Myers wins $752 million in U.S. patent case against Gilead
Reuters
Bristol-Myers Squibb
Gilead Sciences
Kite Pharma
patents
Juno Therapeutics
Flag link:
After Its Celgene Acquisition, Bristol-Myers Squibb's Future Looks Bright
After Its Celgene Acquisition, Bristol-Myers Squibb's Future Looks Bright
Motley Fool
Celgene
M&A
Bristol-Myers Squibb
Flag link:
Vedanta Biosciences initiates first-in-patient study of VE800 in combination with Bristol-Myers Squibb’s Opdivo
Vedanta Biosciences initiates first-in-patient study of VE800 in combination with Bristol-Myers Squibb’s Opdivo
Pharmaceutical Business Review
Vedanta Biosciences
VE800
Bristol-Myers Squibb
Opdivo
cancer
clinical trials
Flag link:

Pages